Opinion|Videos|January 13, 2025
Considerations for Diagnosing Atopic Dermatitis and Assessing Severity
Panelists discuss the diagnostic criteria for atopic dermatitis (AD), highlighting challenges in diagnosis due to the disease’s heterogeneity across factors like age, skin color, and other variables, and explore how this complexity can lead to misdiagnosis or late diagnosis; they also share tips for diagnosing AD, determining disease severity, and incorporating patient-reported outcomes into severity assessments, while examining how advances in treatment and understanding have shaped current perspectives on AD severity.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What diagnostic criteria are considered, and what are some of the challenges of diagnosis (e.g., heterogeneity based on age, skin color, etc.)?
- How can the complexity and heterogeneity of atopic dermatitis potentially lead to misdiagnosis or late diagnosis?
- What tips do you have for diagnosing and determining disease severity?
- How do you define AD disease severity? What parameters do you consider when making the diagnosis of mild, moderate, or severe disease?
- How do you incorporate patient-reported outcomes into determining disease severity?
- How have advances in treatments and in understanding atopic dermatitis changed how we think about severity of disease, if at all?
Advertisement
Related to this article
For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.
Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women
3
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
4
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
5